ArticleClinical and translational radiation oncology2025
Bulky non-small cell lung cancer treated with two-field robust proton lattice boost followed by conventional chemoradiation.
Article in Clinical and translational radiation oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite advances in outcomes for non-small cell lung cancer (NSCLC) with the establishment of adjuvant immunotherapy as the standard of care, locoregional recurrence is still experienced by half of patients with progressive disease. We sought to integrate a novel pencil beam scanning (PBS) spatially fractionated approach into definitive management of bulky non-small cell lung cancer cases. Spatial fractionation via lattice or more commonly GRID has long been of interest as supplement to more conventional radiation regimens for bulky tumors, though requirements for plan robustness and concerns about single-field approaches have previously limited their integration into proton therapy practice. Here we present two cases of bulky NSCLC treated with a novel two-field partially robust PBS lattice boost of 12 Gy followed by standard conventional chemoradiation. Both patients experienced usual mild treatment related toxicities and remain with their bulky lesions controlled in field at more than a year out from treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.